Viatris Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTRS research report →
Range $14 – $26
Price Chart
About the company
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.
- CEO
- Scott Andrew Smith
- IPO
- 1980
- Employees
- 30,000
- HQ
- Canonsburg, PA, US
Get TickerSpark's AI analysis on VTRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.50B
- P/E
- -37.04
- Fwd P/E
- 7.62
- PEG
- 1.05
- P/S
- 1.53
- P/B
- 1.65
- EV/EBITDA
- 12.02
- Div Yield
- 2.45%
- Gross Margin
- 35.22%
- Op Margin
- -0.53%
- Net Margin
- -4.13%
- ROE
- -4.24%
- ROIC
- -0.26%
Latest fiscal year · YoY change
- Revenue
- $14.30B-3.0%
- Gross Profit
- $5.01B-10.8%
- Op Income
- $-2,663,100,000
- Net Income
- $-3,514,900,000-454.2%
- EPS
- $-3.00-466.0%
- OCF Growth
- +0.6%
- FCF Growth
- -2.0%
- 52W High
- $21.20
- 52W Low
- $10.15
- 50D MA
- $18.41
- 200D MA
- $16.37
- Beta
- 0.87
- RSI (14)
- 52
- Avg Volume
- 9.07M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Viatris said Q3 was a strong quarter, raised 2026 guidance again, and highlighted accelerating U.S. and China momentum plus progress on multiple pipeline and Pacira-related growth opportunities.· November 5, 2026
- Q3 revenue was $3.75 billion, adjusted EBITDA was $1.2 billion, and adjusted EPS was $0.71; 9M operational revenue rose 2%, EBITDA 6%, and EPS 8% versus last year.
- Management raised 2026 guidance again, now targeting about 2% operational revenue growth, 6% adjusted EBITDA growth, and 8% adjusted EPS growth at the midpoint.
- North America grew about 7% and Greater China about 10% in the quarter, while Europe and emerging markets were pressured by supply constraints tied to Nashik.
- Adjusted gross margin was 58%, free cash flow was $814 million for the quarter, and the company ended at about 2.9x gross leverage.
- Pacira is still expected to close by the end of November and management expects it to be immediately accretive to 2027 financial metrics, with more than $50 million of annual cost synergies by end-2028.
Third-quarter total revenues were $3.75 billion, adjusted EBITDA was $1.2 billion, and adjusted EPS was $0.71 per share. On an operational basis through the first 9 months, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% versus the prior year. Greater China net sales grew approximately 10% year over year in Q3, North America net sales grew approximately 7%, and supply constraints in Europe and emerging markets reduced total revenue by approximately $100 million in the quarter. Adjusted gross margin was 58%, free cash flow was $814 million in Q3, or $895 million excluding transaction and restructuring-related costs and taxes, and gross leverage ended at approximately 2.9x. For 2026, management raised guidance to midpoint operational growth of about 2% for revenue, 6% for adjusted EBITDA, and 8% for adjusted EPS, excluding Pacira. They also said fourth quarter revenue will still be affected by supply disruptions by approximately $100 million, China growth should remain healthy but moderate further, and Pacira is expected to close before the end of November.
Scott Smith framed the quarter as evidence that Viatris has entered a “new phase of sustained growth,” emphasizing disciplined execution and momentum across the base business. He pointed to North America’s shift toward more durable, higher-margin complex products, continued strength in Greater China, and progress in innovative medicines, including Wakix in Japan, Ryzumvi in the U.S., and upcoming milestones for fast-acting meloxicam, selatogrel, and cenerimod. He was also upbeat on Pacira, calling it a strategic step that would strengthen the U.S. promoted brands business and accelerate the company’s non-opioid pain strategy.
Paul Campbell said Q3 performance was driven by higher-margin growth in Greater China and North America, offset by supply constraints in Europe and emerging markets tied mainly to Nashik. He cited Q3 revenue of $3.75 billion, adjusted gross margin of 58%, free cash flow of $814 million, and gross leverage of about 2.9x, and noted the company remains on track for $120 million of net savings from the strategic review this year. He also said the updated 2026 outlook excludes Pacira, that the transaction should be funded from excess cash and short-term borrowings with minimal leverage impact, and that the company expects more than $50 million in annual cost synergies by end-2028.
Analysts pressed on whether China’s hospital procurement policy was less of a headwind than expected, and management said Q3 was in line with expectations but Q4 should see a greater impact as more provinces roll in; they still expect China to grow next year, though closer to historical low- to mid-single-digit levels. Questions also focused on the sustainability of U.S. growth, Pacira/EXPAREL durability, and cenerimod timing; management said the U.S. portfolio is shifting toward higher-margin complex generics, EXPAREL is difficult to manufacture and they will defend its IP vigorously, and both cenerimod and selatogrel remain on track for first-half 2027 readouts. On the cenerimod data package, Philippe Martin said pooled analysis is prespecified and the interferon-high definition should yield similar results across techniques.
The call showed broad momentum: China is still growing strongly, North America is accelerating, and the portfolio mix is shifting toward higher-margin products and launches. Management also sounded confident about 2027, citing Pacira, the U.S. innovative medicines buildout, and multiple pipeline catalysts that could add to growth.
Management acknowledged real headwinds from supply constraints at Nashik, which they said cut Q3 revenue by about $100 million and should again pressure Q4 by about $100 million. They also flagged China growth moderating as provincial policy changes spread, plus potential 2027 headwinds from losses of exclusivity, including Amitiza in Japan and the full-year impact of isosulfan blue in the U.S.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 1.15B
- Float Shares
- 1.14B
of shares held by institutions
1,068 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VTRS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Nov 18, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 31, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Feb 25, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 19, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Mar 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 14, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Jan 31, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 22 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Aug 1, 22 | Filing → |
| Carol Devine MillerHouse · WV03 | Sell | Mar 4, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 138.18M | ▼ 2.09M |
| Fmr LLC | 133.57M | ▲ 36.91M |
| Blackrock, Inc. | 85.22M | ▼ 795.01K |
| Vanguard Capital Management LLC | 75.18M | ▼ 863.67K |
| Davis Selected Advisers | 72.40M | ▼ 2.83M |
| Price T Rowe Associates Inc | 58.72M | ▼ 9.49M |
| Vanguard Portfolio Management LLC | 54.30M | ▲ 22.20K |
| State Street Corp | 46.37M | ▼ 6.69M |
| Rubric Capital Management LP | 36.00M | ▲ 1.83M |
| Geode Capital Management, LLC | 33.04M | ▲ 236.72K |
| Invesco Ltd. | 22.05M | ▲ 1.28M |
| Ameriprise Financial Inc | 17.83M | ▼ 983.23K |
Held by 1,053 ETFs
Biggest fund positions in VTRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Groothuis Leo Frans | other | 2,469 |
| Sep 30, 26 | SIMMONS DAVID S | other | 2,117 |
| Aug 15, 26 | Enrietti Andrew | other | 25,134 |
| Aug 15, 26 | Enrietti Andrew | other | 999 |
| Aug 15, 26 | Enrietti Andrew | other | 435 |
| Aug 15, 26 | Enrietti Andrew | other | 10,931 |
| Aug 15, 26 | Enrietti Andrew | other | 25,134 |
| Aug 15, 26 | Enrietti Andrew | other | 998.364 |
| Jun 30, 26 | SIMMONS DAVID S | other | 2,362 |
| Jun 30, 26 | Groothuis Leo Frans | other | 2,756 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VTRS coverage
Recent articles, reports, and earnings notes.
No research on VTRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VTRS report →All You Need to Know About Viatris (VTRS) Rating Upgrade to Strong Buy
zacks.com · Nov 20
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Are Investors Undervaluing Viatris (VTRS) Right Now?
zacks.com · Nov 17
Viatris Completes Acquisition of Pacira BioSciences
prnewswire.com · Nov 17
Viatris Inc. (VTRS) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
prnewswire.com · Nov 16
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year
prnewswire.com · Nov 12
Viatris to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.